<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251262</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2013/31</org_study_id>
    <nct_id>NCT02251262</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection</brief_title>
  <acronym>ENDOTEP</acronym>
  <official_title>Assessment of Diagnostic Accuracy of 18FDG-PET-CT in Patients With Suspicion of Pacing or Defibrillation Lead Infection: a Prospective Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With aging of the general population and broadening indications, the number of pacemaker
      recipients is steadily increasing. The incidence of infections of the implanted material, a
      dreaded major complication, is also rising. The diagnosis is evident in presence of an
      abscessed pocket, cutaneous breakthrough of the pulse generator or vegetations attached to
      the lead. On the other hand, a proportion of patients present with less specific clinical
      manifestations and a pacemaker recipient may be recurrently hospitalized for an infectious
      disorder of unknown origin despite detailed investigations. Without proof of lead infection,
      removal of the system without confirmation of its infection is usually proposed, despite the
      known morbidity and mortality associated with the extraction procedure (0.5 to 2%). Positive
      culture of the leads implies that the leads were involved in the infectious process. In
      recent years, 18FDG-PET-CT scan has made promising contributions in different areas including
      imaging to detect infection at different organ sites. Absence of hyperfixation of the lead,
      identified by 18FDG-PET/CT scan may be an accurate sign of absence of pacing system
      infection.

      The extraction of intracardiac implanted material, when it is indicated by the current
      standard strategy, may result in negative bacteriological cultures in 10 to 25% of patients,
      even when they did not receive antibiotics before extraction.

      The hypothesis of the study is that a new strategy adding 18FDG-PET-CT to the current
      strategy may avoid or reduce these false-positives.

      Therefore it is hypothesized that the sensitivity of 18FDG-PET-CT will be high enough to
      avoid unnecessary extractions of uninfected leads, resulting in a high negative predictive
      value of the new diagnostic strategy incorporating 18FDG-PET-CT. The present study aims at
      providing valid estimates of diagnostic accuracy parameters of 18FDG-PET-CT, especially its
      sensitivity.

      For this clinical study, firstly, 18FDG-PET-CT exam will be performed in patients, with
      suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit;
      secondarily, an intervention for the extraction of the intra-cardiac material, under general
      anesthesia, will be practiced and then a bacteriological culture for extracted material will
      be required.

      The end of study visit is complete the last day of material extraction. The follow up will
      last 2 to 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2015</start_date>
  <completion_date type="Anticipated">June 22, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A semi-quantitative visual interpretation of 18FDG-PET-CT in the diagnosis of infection of intracardiac device.</measure>
    <time_frame>up to 48 hours after inclusion (exceptionally, up to 7 days if the patient is not under antibiotic therapy)</time_frame>
    <description>Index tests will be interpreted by nuclear medicine physician from the center where the patient was included with a semi-quantitative visual score.
Moreover, all 18FDG-PET-CT recordings will be sent to the coordinating center for centralized interpretation blind to the preceding one.
All 18FDG-PET-CT recordings will be stored until interpretation, and not used for the clinical management of the patient.
Index test interpretations will be carried out blind to any other information on the patient (clinical, biology,…).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Infections of the Implanted Material</condition>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>Whole-body 18FDG-PET-CT scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Whole-body 18FDG-PET-CT scan</intervention_name>
    <description>18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.</description>
    <arm_group_label>Whole-body 18FDG-PET-CT scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders

          -  Age &gt; 18 years

          -  Patient referred for extraction of cardiac material (box and lead(s)) in the context
             of suspicion of material infection, including a patient with pocket infection.

          -  Possibility of carrying out PET-CT no more than 48 hours before extraction (or,
             exceptionally, no more than 7 days if the patient is not under antibiotic therapy).

          -  Informed written consent

          -  Affiliation to a social security system

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Patients with recent implantation (less than 2 months)

          -  Subjects placed under judicial protection

          -  Subjects participating in another study that includes an exclusion period on-going at
             the time of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre BORDACHAR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul PEREZ, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre BORDACHAR, MD</last_name>
    <email>pierre.bordachar@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie SERIS</last_name>
    <email>elodie.seris@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital A. Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal DEFAYE, MD</last_name>
      <email>PDefaye@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Daniel FAGRET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal DEFAYE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital R. Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier KLUG, MD</last_name>
      <email>didier.klug@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Didier KLUG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude HOSSEIN-FOUCHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude DEHARO, MD</last_name>
      <email>jean-claude.deharo@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Claude DEHARO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier MUNDLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre BORDACHAR, MD</last_name>
      <email>pierre.bordachar@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elodie SERIS</last_name>
      <email>elodie.seris@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre BORDACHAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence BORDENAVE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ghoufrane TLILI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia PEUCHANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge BOVEDA, MD</last_name>
      <email>sboveda@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Serge BOVEDA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric BULLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas SADOUL, MD</last_name>
      <email>n.sadoul@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas SADOUL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Yves MARIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2014</study_first_submitted>
  <study_first_submitted_qc>September 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pacemaker</keyword>
  <keyword>Endocarditis</keyword>
  <keyword>18FDG-PET-CT</keyword>
  <keyword>Diagnostic accuracy</keyword>
  <keyword>Pacing or defibrillation lead</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

